What is PharmaCyte Biotech Inc Annual Net Profit?

PharmaCyte Biotech Inc Annual Net Profit rose 107.73% in the last year to $0.33 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is PharmaCyte Biotech Inc Price to Earning Ratio?

PharmaCyte Biotech Inc Price to Earning Ratio is 0.4, lower than its sector PE ratio of 3.14.

What is PharmaCyte Biotech Inc Stock Price?

PharmaCyte Biotech Inc Stock Price fell 44.34% and underperformed its sector by 53.03% in the past year.

What is PharmaCyte Biotech Inc Quarterly Net profit?

PharmaCyte Biotech Inc Quarterly Net profit fell 391.55% YoY to $3.05 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

What is PharmaCyte Biotech Inc Return on Equity(ROE)?

PharmaCyte Biotech Inc Return on Equity(ROE) for the last financial year was -34.36%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is PharmaCyte Biotech Inc Mutual Fund Holding?

PharmaCyte Biotech Inc Mutual Fund Holding increased by 0.02% in the last quarter to 8.63.

What is PharmaCyte Biotech Inc Institutional Holding?

PharmaCyte Biotech Inc Institutional Holding remained the same in the last quarter at 9.84%.

How is the PharmaCyte Biotech Inc today?

The PharmaCyte Biotech Inc today is trading in the green, up by 4.42% at 1.18.

How has PharmaCyte Biotech Inc performed historically?

The PharmaCyte Biotech Inc is currently trading up 4.42% on an intraday basis in the past week the index fell -1.67%. The index has been down -29.34% in the past quarter and fell -44.34% in the past year. You can view this in the overview section.

PharmaCyte Biotech Inc XNAS: PMCB

PharmaCyte Biotech Inc Live Share Price Today, Share Analysis and Chart

Name: PharmaCyte Biotech Inc: Is Infosys Ltd. worth buying?
Item: PharmaCyte Biotech Inc
Rating: 2.42975
Author: Trendlyne DVM scores

Download real time

1.18 0.05 (4.42%)

New 52W Low in past week

340 XNAS Volume

XNAS 22 Apr, 2025 9:54 AM (EDT)

Board Meeting

The next board meeting for PharmaCyte Biotech Inc is on 29 Apr 2025 for the purpose of PharmaCyte Biotech Inc Annual General Meeting for 2025 See details

PharmaCyte Biotech Inc Key Metrics

My Metrics

Select

Market Capitalization Low in industry Unavailable in chosen country	8.1
PE TTM Below industry Median Unavailable in chosen country	0.4
Price to Book Low in industry Unavailable in chosen country	0.2
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	9.8
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-391.5
Net Profit TTM Growth % Market Leader Unavailable in chosen country	1,877.7
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-28.6
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-34.4
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-25.9

All financials are in USD Million and price data in USD

Not Eligible

Affordable Valuation

65.0 / 100

Technically Bearish

32.2 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

Not enough data available

PharmaCyte Biotech Inc Stock Price Analysis

Day Price Range 4.4% 1 Day return Unavailable in chosen country	1.2 (LTP) 1.21.2 LowHigh
Week Price Range -1.7% 1 Week return Unavailable in chosen country	1.2 (LTP) 11.3 LowHigh
Month Price Range -25.3% 1 Month return Unavailable in chosen country	1.2 (LTP) 11.6 LowHigh
52 Week Price Range -44.3% 1 Year return Unavailable in chosen country	1.2 (LTP) 12.4 LowHigh

View full Share Price History

PharmaCyte Biotech Inc Live Price Chart

Switch to TradingView

Fetching data ...

PharmaCyte Biotech Inc Stock Analysis

PharmaCyte Biotech Inc stock analysis with key metrics, changes, and trends.

PharmaCyte Biotech Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$0.33 M	107.73%	positive	Annual Net Profit rose 107.73% in the last year to $0.33 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	0.4	-	positive	Price to Earning Ratio is 0.4, lower than its sector PE ratio of 3.14.
Stock Price	$1.18	-44.34%	negative	Stock Price fell 44.34% and underperformed its sector by 53.03% in the past year.
Quarterly Net profit	$3.05 M	391.55%	negative	Quarterly Net profit fell 391.55% YoY to $3.05 M. Its sector's average net profit growth YoY for the quarter was -41.98%.
Return on Equity(ROE)	-34.36 %	-34.36%	negative	Return on Equity(ROE) for the last financial year was -34.36%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	8.63 %	0.02%	positive	Mutual Fund Holding increased by 0.02% in the last quarter to 8.63.
Institutional Holding	9.84 %	0%	neutral	Institutional Holding remained the same in the last quarter at 9.84%.

VIEW LESS

Loading data..

PharmaCyte Biotech Inc - Company Profile

What does PharmaCyte Biotech Inc do?

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

PharmaCyte Biotech Inc Management structure

All Gross Remunerations are in USD

Mr. Joshua Nathaniel Silverman

Interim Chairman of the Board, Interim Chief Executive Officer and Interim President

787.92 K

2024

Gross Remuneration

Year

Mr. Carlos A. Trujillo

Chief Financial Officer and Principal Accounting Officer

586.56 K

2024

2024

Gross Remuneration

Year

PharmaCyte Biotech Inc Live Share Price Today, Share Analysis and Chart

New 52W Low in past week

PharmaCyte Biotech Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

PharmaCyte Biotech Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

PharmaCyte Biotech Inc Live Price Chart

PharmaCyte Biotech Inc Stock Analysis

PharmaCyte Biotech Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 107.73% in the last year to $0.33 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is 0.4, lower than its sector PE ratio of 3.14.

Stock Price fell 44.34% and underperformed its sector by 53.03% in the past year.

Quarterly Net profit fell 391.55% YoY to $3.05 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Return on Equity(ROE) for the last financial year was -34.36%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.02% in the last quarter to 8.63.

Institutional Holding remained the same in the last quarter at 9.84%.

PharmaCyte Biotech Inc - Company Profile

What does PharmaCyte Biotech Inc do?

PharmaCyte Biotech Inc Management structure

Mr. Joshua Nathaniel Silverman

Interim Chairman of the Board, Interim Chief Executive Officer and Interim President

Mr. Carlos A. Trujillo

Chief Financial Officer and Principal Accounting Officer

PharmaCyte Biotech Inc Board of directors

Dr. Michael M. Abecassis, M.D.

Independent Director

Mr. Robert Weinstein

Independent Director

Mr. Jonathan L. Schechter

Independent Director

Mr. Wayne R. Walker

Independent Director

Mr. Joshua Nathaniel Silverman

Interim Chairman of the Board, Interim Chief Execu

PharmaCyte Biotech Inc FAQ

How is PharmaCyte Biotech Inc today?

PharmaCyte Biotech Inc today is trading in the green, and is up by 4.42% at 1.18.

How has PharmaCyte Biotech Inc performed historically?

PharmaCyte Biotech Inc is currently trading up 4.42% on an intraday basis. In the past week the stock fell -1.67%. stock has been down -29.34% in the past quarter and fell -44.34% in the past year. You can view this in the overview section.